Diabetes Research and Clinical Practice - Volume 120 - Supplement 1 - October 2016

214 / 244

55.7%, and 54.8. (P < 0.001). The overall concordance with
Martin LDL-C was 70.0% for HbA1c < 6.5 vs. 67.6% for HbA1c
between 6.5 –8 vs. 67.7% for HbA1c between 8–9 vs. 67.3 for
HbA1c ≥9 (P < 0.001). The accuracy of Lee and Hu formula was
slightly inferior to the Martin formula, but better than FF,
especially in subjects with high HbA1c level (P < 0.001,
respectively).
Conclusion: High HbA1c was associated with poor accuracy in
LDL-C estimation. The Lee and Hu formula cost less andmaybe
a simple form to estimate LDL-C in clinical practice.
PJ-07
Tramadol is a risk factor for hypoglycemia in diabetic patients
in Taiwan
Hsin Hung CHEN1,2*. 1Nantou Christian Hospital, 2Chung Shan
Medical University, Taiwan
Aim: To evaluate the association between tramadol and
hypoglycemia in diabetic Taiwanese.
Method: Our study data were derived from a subset of the
National Health Insurance Research Database. Diabetic
patients aged 20 years or older with prescribed tramadol
prescription were in the tramadol group, compared to
nontramadol group.
Results: During a mean follow-up of 2 to 2.7 years for these two
groups, the overall incidences of hypoglycemia (per 1,000
person-y) were significantly higher in tramadol group.
According to the multivariable analyses, the tramadol group
exhibited a significantly greater risk of hypoglycemia.
Conclusion: Tramadol use increases hypoglycemia in diabetic
Taiwanese.
PJ-08
Associations between type 2 diabetes and peptic ulcer disease
in Taiwan
Hsin Hung CHEN1,2*. 1Nantou Christian Hospital, 2Chung Shan
Medical University, Taiwan
Purpose: To evaluate the association between type 2 diabetes
mellitus (T2DM) and peptic ulcer disease (PUD) in Taiwan.
Methods: Patients diagnosed with T2DM for the first time
between 2000 and 2005 was included and excluded patients
diagnosed with PUD before the index date. Only patients who
were treated for PUD by using proton-pump inhibitors, H2-
receptor antagonists, or both were included. Distributions of
sex, age, comorbidity, and medication were compared
between the T2DM and non-T2DM groups to determine
whether T2DM was a risk factor for PUD.
Results: During the study period, the T2DM group exhibited a
significantly higher risk of developing PUD than did the non-
T2DMgroup. After stratification by comorbidity, the significant
association of the T2DM group with the increased risk of PUD
development is still in our study.
Conclusion: This cohort study shows that T2DM increases the
risk of developing PUD in Taiwan.
PJ-10
Meta-analysis of the insulin dosage in Chinese type 2 diabetes
patients receiving insulin treatment
Xiaoling CAI1*, Wenjia YANG1, Xueying GAO1, Lingli ZHOU1,
Xueyao HAN1, Linong JI1. 1Peking University People’s
Hospital, China
Aim: To evaluate the insulin dosage in Chinese type 2 diabetes
patients receiving various kinds of insulin treatment.
Methods: The MEDLINE, EMBASE, CNKI and Wan Fang
databases were searched and qualified studies were included.
The inclusion criteria were as following: (1) randomized
controlled trial in type 2 diabetes patients; (2) Chinese
participants; (3) insulin treatment in one arm or both arms in
the trial; (4) study duration more than 12 weeks.
Results: Totally 88 qualified studies were included. According
to randomized controlled trials, in patients receiving basal
bolus insulin treatment, daily insulin dosage for the long-
acting insulin analog in combination with rapid insulin analog
was 28.30 u/day, daily insulin dosage for the NPH combined
with regular insulin was 42.16 u/day, daily insulin dosage for
the NPH combined with rapid insulin analog was 39.41 u/day.
In patients receiving basal insulin with oral hypoglycemic
agents treatment, daily insulin dosage for the long-acting
insulin analog was 18.33 u/day, daily insulin dosage for NPH
insulin was 16.34 u/day. In patients receiving premixed insulin
treatment, daily insulin dosage for premixed insulin analog
with oral hypoglycemic agents was 26.41 u/day, daily insulin
dosage for premixed insulin analog alone was 36.14 u/day,
daily insulin dosage for premixed human insulin with oral
hypoglycemic agents was 29.91 u/day, daily insulin dosage for
premixed human insulin alone was 38.42 u/day.
Conclusion: This meta-analysis was the first meta-analysis
focused on the insulin dosage in Chinese type 2 diabetes
patients which provided more comprehensive clinical evi-
dence on the insulin dosage among different insulin treat-
ments in treating Chinese type 2 diabetes patients.
PJ-11
Insulin resistance distribution and cut off value in Korea: From
the 2008–2010 Korean national health and nutrition
examination survey
Jee-sun JEONG1, Kyung-jin YUN1, Mee Kyoung KIM1,
Ki-Hyun BAEK1, Ki-Ho SONG1, Hyuk-Sang KWON1*. 1Yeouido
St. Mary’s Hospital, Korea
The subject of this study is to identify the distribution of
HOMA-IR in Korea. And we investigated the cut off values of
HOMA-IR that related with prevalence rate of metabolic
syndrome, especially according to gender and menopause
state.
We analysed the data of Korean National Health and
Nutrition Examination Survey in 2008–2010. We conducted
this study for participant aged 20 years or older and excluded
the subject who had diabetes or fasting serum glucose
>126 mg/dL. Finally, 11,121 participants were gathered and
they were classified into three groups (4,911 men, 3,597
premenopausal women, 2,613 postmenopausal women). We
used modified Adult Treatment Panel III criteria to define
metabolic syndrome.
In our study, the mean HOMA-IR was 2.11(2.07–2.15) for men,
2.0(1.97–2.04) for premenopausal women, and 2.14(2.2 –2.19) for
postmenopausal women. Incidence of metabolic syndrome
was 20.6% in men, 8.9% in premenopausal women, and 40.4%
in postmenopausal women. The first cut off values for
metabolic syndrome in men, premenopausal women and
postmenopausal women is 2.23(sensitivity 70.6%, specificity
66.9%), 2.39(sensitivity 72.3%, specificity 76.4%) and 2.48
(sensitivity 51.9%, specificity 80.2%), respectively. The preva-
lence rate of metabolic syndrome associated to first HOMA-IR
cut off value is 22.9% in men, 13.7% in premenopausal women
and 51.6% in postmenopausal women. The second cut off
value was around 3.2 in three groups. The prevalence rate of
metabolic syndrome associated to second HOMA-IR cut off
value is 50.8% in men, 42.5% in premenopausal women and
71.6% in postmenopausal women.
In conclusion, first cut off value of HOMA-IR were 2.2–2.5 and
second cut off value of HOMA-IR were 3.2 in Korea. And cut off
values of HOMA-IR for metabolic syndrome was different
in accord with gender and menopausal status. When we
estimated the HOMA-IR and prevalence of metabolic syn-
drome, we should consider to gender and menopausal status
of participants.
Poster Presentations / Diabetes Research and Clinical Practice 120S1 (2016) S65–S211 S196